NASDAQ$CELC
Celcuity Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Celcuity's financial performance for Q4 2020 and the full year was reported, highlighting collaborations and progress in clinical trials.
Celcuity Inc. reported a net loss of $2.55 million for the fourth quarter of 2020, compared to a net loss of $1.81 million for the fourth quarter of 2019. The company's operating expenses were $2.55 million, up from $1.90 million in the same quarter of the previous year. Celcuity had cash and cash equivalents of $11.6 million as of December 31, 2020.
- Announced clinical trial collaborations with Massachusetts General Hospital, UCLA, Vanderbilt, Puma Biotechnology, Sarah Cannon Research Institute, and Pfizer Inc.
- Total operating expenses were $2.55 million for the fourth quarter of 2020, compared to $1.90 million for the fourth quarter of 2019.
- Net loss for the fourth quarter of 2020 was $2.55 million, or $0.25 per share, compared to a net loss of $1.81 million, or $0.18 per share, for the fourth quarter of 2019.
- At December 31, 2020, Celcuity had cash and cash equivalents of $11.6 million, compared to cash and cash equivalents of $18.7 million at December 31, 2019.
Headline financials
Revenue & EPS history
Celcuity · Revenue · Quarterly
$0
Forward guidance
Celcuity anticipates announcing additional clinical trial collaborations in the first half of 2021 and expects interim results from the FACT-1 and FACT-2 trials in late 2021 or early 2022.
Tailwinds
- Expect to announce additional clinical trial collaborations in the first half of 2021.
- Continue to develop CELsignia RAS test for breast and ovarian cancers, and plan to report data on these new tests in the first half of 2021.
- Interim results from the FACT-1 and FACT-2 trials are expected in late 2021 or early 2022.
Headwinds
- The COVID-19 pandemic has impacted Celcuity's business and results of operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.9%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+23.3%
Q4 2023
Best reaction
-13.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.5% | -4.7% | -32.5% | |
| Q3 2025 | +1.1% | +7.6% | +23.6% | |
| Q2 2025 | +0.1% | -6.0% | +5.8% | |
| Q1 2025 | -2.6% | -1.9% | +11.5% | |
| Q4 2024 | -8.1% | -14.4% | +6.8% | |
| Q3 2024 | -13.5% | -14.8% | -14.5% | |
| Q2 2024 | -6.2% | +3.0% | -10.9% | |
| Q1 2024 | +4.6% | -0.5% | -11.0% | |
| Q4 2023 | +23.3% | +18.6% | -9.1% | |
| Q3 2023 | +11.3% | +18.7% | +37.4% | |
| Q2 2023 | -1.0% | -1.2% | -8.7% | |
| Q1 2023 | +2.2% | +4.7% | +9.5% | |
| Q4 2022 | -5.0% | +3.7% | -3.2% | |
| Q3 2022 | +3.0% | -0.5% | -6.7% | |
| Q2 2022 | -1.0% | -4.3% | -14.2% | |
| Q1 2022 | +2.8% | +6.5% | +57.6% | |
| Q4 2021 | -2.8% | +0.0% | -16.8% | |
| Q3 2021 | -5.9% | -7.7% | -26.6% | |
| Q2 2021 | -1.3% | +2.3% | +5.1% | |
| Q1 2021 | -4.5% | -0.8% | -0.8% | |
| Q4 2020 | +1.1% | +7.4% | -3.9% | |
| Q3 2020 | +0.5% | +64.0% | +93.3% | |
| Q2 2020 | -0.2% | -6.9% | -11.3% | |
| Q1 2020 | -2.4% | -13.8% | +90.3% | |
| Q4 2019 | -4.8% | -3.7% | -23.5% | |
| Q3 2019 | +1.4% | +1.0% | -23.1% | |
| Q2 2019 | +0.7% | -0.4% | -14.9% | |
| Q1 2019 | -2.5% | +0.2% | -6.8% | |
| Q4 2018 | -4.7% | -8.5% | -12.8% | |
| Q3 2018 | -7.2% | -6.2% | -17.8% | |
| Q2 2018 | -1.1% | +2.8% | -15.0% | |
| Q1 2018 | -4.0% | -2.4% | -2.2% | |
| Q4 2017 | -2.4% | -9.9% | +18.6% | |
| Q3 2017 | -5.6% | -15.7% | -13.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro